Chiril Voloc, D. Sirbu, Alexandru Voloc, Stanislav Eni, Daniel Sirbu
{"title":"骨质疏松症患者因双磷酸盐引起的颌骨骨松症","authors":"Chiril Voloc, D. Sirbu, Alexandru Voloc, Stanislav Eni, Daniel Sirbu","doi":"10.53530/1857-1328.23.1.11","DOIUrl":null,"url":null,"abstract":"Bisphosphonate–induced maxillary osteonecrosis represents a pathology of the oral cavity characterized by the presence of ulcerations, exposure of necrotic bone tissue and secondary complications. Purpose: to evaluate the effectiveness of preventive measures and treatment plan of bisphosphonate–induced maxillary osteonecrosis in patients with osteoporosis. Material and methods: In the study there are 3 female patients — DE — 65, LV — 85 and VM — 73 years of age respectively, to whom bisphosphonates were administered, two of them — orally and one — intravenously. The following investigations were performed: clinical, radiological examination (OPG and CBCT), osteodensitometry and beta–cross–laps bone marker analysis, and rheumatologist consultation. Results: Examination and treatment of patients was performed in 2 cases, with follow up for 1 year on average. The beta–cross–laps bone marker was respectively: DE–0.26 ng/mL, LV–0.22 ng/mL, VM–0.24 ng/ mL. Radiological examination revealed signs of sinusitis, irregular bone margins, increased porosity and in one clinical case — bone fragment detachment. Medicinal and surgical treatment was carried out for issues in the oral cavity. Conclusion: Early detection of bisphosphonate–induced osteonecrosis, as well as interdisciplinary collaboration with the physician rheumatologist, results in a decrease in the occurrence of secondary complications.","PeriodicalId":122574,"journal":{"name":"Journal of Stomatological Medicine","volume":"110 5-6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bisphosphonate–induced osteonecrose of the jaws in patients with osteoporosis\",\"authors\":\"Chiril Voloc, D. Sirbu, Alexandru Voloc, Stanislav Eni, Daniel Sirbu\",\"doi\":\"10.53530/1857-1328.23.1.11\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Bisphosphonate–induced maxillary osteonecrosis represents a pathology of the oral cavity characterized by the presence of ulcerations, exposure of necrotic bone tissue and secondary complications. Purpose: to evaluate the effectiveness of preventive measures and treatment plan of bisphosphonate–induced maxillary osteonecrosis in patients with osteoporosis. Material and methods: In the study there are 3 female patients — DE — 65, LV — 85 and VM — 73 years of age respectively, to whom bisphosphonates were administered, two of them — orally and one — intravenously. The following investigations were performed: clinical, radiological examination (OPG and CBCT), osteodensitometry and beta–cross–laps bone marker analysis, and rheumatologist consultation. Results: Examination and treatment of patients was performed in 2 cases, with follow up for 1 year on average. The beta–cross–laps bone marker was respectively: DE–0.26 ng/mL, LV–0.22 ng/mL, VM–0.24 ng/ mL. Radiological examination revealed signs of sinusitis, irregular bone margins, increased porosity and in one clinical case — bone fragment detachment. Medicinal and surgical treatment was carried out for issues in the oral cavity. Conclusion: Early detection of bisphosphonate–induced osteonecrosis, as well as interdisciplinary collaboration with the physician rheumatologist, results in a decrease in the occurrence of secondary complications.\",\"PeriodicalId\":122574,\"journal\":{\"name\":\"Journal of Stomatological Medicine\",\"volume\":\"110 5-6\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Stomatological Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.53530/1857-1328.23.1.11\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Stomatological Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53530/1857-1328.23.1.11","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Bisphosphonate–induced osteonecrose of the jaws in patients with osteoporosis
Bisphosphonate–induced maxillary osteonecrosis represents a pathology of the oral cavity characterized by the presence of ulcerations, exposure of necrotic bone tissue and secondary complications. Purpose: to evaluate the effectiveness of preventive measures and treatment plan of bisphosphonate–induced maxillary osteonecrosis in patients with osteoporosis. Material and methods: In the study there are 3 female patients — DE — 65, LV — 85 and VM — 73 years of age respectively, to whom bisphosphonates were administered, two of them — orally and one — intravenously. The following investigations were performed: clinical, radiological examination (OPG and CBCT), osteodensitometry and beta–cross–laps bone marker analysis, and rheumatologist consultation. Results: Examination and treatment of patients was performed in 2 cases, with follow up for 1 year on average. The beta–cross–laps bone marker was respectively: DE–0.26 ng/mL, LV–0.22 ng/mL, VM–0.24 ng/ mL. Radiological examination revealed signs of sinusitis, irregular bone margins, increased porosity and in one clinical case — bone fragment detachment. Medicinal and surgical treatment was carried out for issues in the oral cavity. Conclusion: Early detection of bisphosphonate–induced osteonecrosis, as well as interdisciplinary collaboration with the physician rheumatologist, results in a decrease in the occurrence of secondary complications.